July 2022 - Page 2 of 3

MondayJul 18, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recoveryThis has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effectiveDehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertensionThe recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD spaceLexaria is excited…

ThursdayJul 14, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa

Lexaria's patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitorsDehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastesThe global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030, resulting in a revenue forecast of $22.05 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that Boldt Runners Corporation, licensee of its patented…

WednesdayJul 13, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Solidifies Its Detroit Presence with New Office in Troy; Poised to Be Integral Part of Latest Auto Trends

Cepton has opened a new dedicated automotive office in Metro Detroit - a clear sign of its growing relationship with General Motors and the American auto industryCompany solidifies itself as a key player in lidar; Metro Detroit office serves as automotive hub providing local support to OEM and Tier 1 partnersCepton boasts collaboration with Ford, expands its ongoing partnership with Koito Manufacturing, a leading tier-1 automotive lighting supplier, and remains engaged with the top 10 global automakers "I'm incredibly proud that our Silicon Valley company, Cepton, has earned Detroit's trust," said Dr. Jun Pei, Cepton (NASDAQ: CPTN) Co-Founder and CEO,…

TuesdayJul 12, 2022 12:00 pm

Emerging iGaming Technology Trends Fuel Golden Matrix Group Inc.’s (NASDAQ: GMGI) B2B Growth Strategy

Enhanced graphics, Gamification, AI-powered loyalty systems and data analytics redefining iGaming experience and generating higher player yields for online operators.GMGI sets industry standard, offers 10,000+ games across 25+ providersCompany provides highly configurable, modular, white-label, turnkey gaming platforms compatible with all major operating systems, browsers, devicesCompany recently reported 221% Q2-2022 growth, 15 consecutive profitable quarters Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, continues its steady growth trajectory by leveraging several emerging technology trends. In particular, the company is leveraging its go-to Loyalty platform that incorporates a Gamification component. Gamification adds an extra…

TuesdayJul 12, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs

Lexaria is a global innovator in drug delivery platformsThe company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeuticsBioavailability is the fraction of a drug that reaches the site of action or systemic circulationWhile drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailabilityDehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM)…

MondayJul 11, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment

Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent fatal cancer glioblastoma (“GBM”)CNS is developing the drug candidate Berubicin as an alternative to the standard-of-care chemotherapy agent, Lomustine, with the hope that Berubicin will prove itself at least as effective and potentially more so Berubicin has demonstrated the capacity to cross the blood-brain barrier in order to attack central nervous system tumors directly, which grants it…

MondayJul 11, 2022 10:30 am

Flora Growth Corp.’s (NASDAQ: FLGC) Shareholders Vote in Favor of All Proposals Submitted for Approval; Elect Brandon Konigsberg to Board of Directors

Shareholders approve all proposals submitted at this year’s annual shareholders’ meeting, including board membersAmong the seven members of the Board of Directors elected, six were incumbents, making Brandon Konigsberg the newest addition to the BoardMr. Konigsberg will lend his years of experience, having held key leadership positions in various organizations in the countryLuis Merchan, Flora Growth’s Chairman and CEO, noted that Mr. Konigsberg’s appointment would help the organization achieve rapid financial growth and maximize shareholder value Annual shareholders’ meetings are usually landmark moments of shareholder democracy, offering shareholders an opportunity to participate in the company’s decisions and offer their input…

MondayJul 11, 2022 9:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Is ‘One to Watch’

Fr8Tech aims to revolutionize cross-border shipping by providing shippers flexibility, visibility and simplicityThrough Fr8app, the company reduces human touch points and expedites load booking timesFr8Tech seeks to lessen the carbon footprint of the logistics industry by minimizing empty miles for transportation firms and reducing overall paper consumptionThe company’s established foothold in Mexico, the U.S.’s largest trade partner, is key to its current efforts to promote sustainable growth in the cross-border shipping industryU.S.-Mexico cross-border annual freight spending is estimated at $385 billionThe company is led by a strong management team with decades of experience in transportation and technology Freight Technologies (NASDAQ:…

ThursdayJul 07, 2022 11:15 am

Gambling Market Setting New Records, a Perfect Storm Brewing for Golden Matrix Group Inc. (NASDAQ: GMGI)

The iGaming market is expected to reach $127 billion by 2027Golden Matrix Group provides turnkey gaming platforms giving iGaming operators access to over 10,000 games, state of the art loyalty and customer retention systemsGMGI recently acquired and 80% stake in RKings, helping boost revenue 221% in Q1 to $8.48 million as it ventures into the Mexican markets and ESports industry In 2021, the U.S. commercial gaming industry generated revenue of $53 billion, smashing the previous record set in 2019 at $43.65 billion. With new markets coming online, more records are almost certainly in the cards as evidenced by a Q1…

ThursdayJul 07, 2022 10:30 am

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patientsCycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indicationsCycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugsThere is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drugThere is also significant preliminary safety precedent for Samarium-153, as…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: July 2022